RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today voluntarily initiated a recall
of all lots of the Ciprofloxacin Injection 2 mg/mL (Intravenous Infusion) as a
precautionary measure. There are currently no reports in Canada of any adverse
reactions or adverse events as a result of the administration of Ciprofloxacin
Injection to a patient.


This product was manufactured by Claris Lifesciences Limited ("Claris") and
therefore the product will bear both the BioSyent Pharma Inc. and Claris
Lifesciences Limited names on the product and packaging.


This precautionary recall is being undertaken due to complaints in the United
States on certain other medications manufactured by Claris which have
subsequently been recalled. Claris has voluntarily extended this recall to
include Ciprofloxacin Injection in the United States.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024